MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
The ATAI Life Sciences IPO could come as soon as the end of January. What does this mean for psychedelic stock investors?
Numinus announces a product development agreement with Optimi Health Corp.
Cybin Corp updates investors on its IP development
Psychedelic Stock Watch connects the dots regarding Mind Cure's clinic launch and latest product development news.
Mind Cure's iSTRYM digital therapeutics platform is designed to provide real-time data regarding patient care.
The new Horizons Psychedelic Stock Index ETF will add new demand and increased visibility for psychedelic drug stocks.
Mind Cure's nootropic products are set to launch across 17 locations within North America starting Feb, 2021.
Health Canada issues its first Section 56 Exemption for psilocybin use to an Alberta resident.
Two of the most powerful voices in new media are advocating for the mental health benefits of psychedelics in a big way.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now